STOCK TITAN

Teleflex Inc - TFX STOCK NEWS

Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.

Teleflex Incorporated (NYSE: TFX) is a leading global provider of specialty medical devices for critical care and surgical procedures. Headquartered in Wayne, Pennsylvania, Teleflex employs approximately 12,000 people worldwide and serves healthcare providers in more than 150 countries.

The company’s diverse product portfolio spans across several key segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and others. These segments collectively cover a wide range of medical needs, from complex surgical interventions to everyday critical care requirements.

Teleflex’s vascular access segment, contributing 24% to 2023 sales, includes innovative solutions for secure and reliable bloodstream access. The interventional segment, accounting for 17%, focuses on cutting-edge devices for minimally invasive procedures. Anesthesia and surgical segments, with 13% and 14% of sales respectively, offer advanced tools and technologies to improve patient outcomes during surgeries.

The company’s interventional urology segment, noted for its UroLift™ System, addresses benign prostatic hyperplasia (BPH) with minimally invasive solutions that preserve patient quality of life. Original-equipment manufacturing and other segments contribute 11% and 10% of sales respectively, underscoring Teleflex’s broad manufacturing capabilities and diverse product offerings.

Teleflex's geographic exposure is primarily in the United States, which generates 60% of its revenue, with international markets contributing the remainder. The company’s global reach and diverse product lines highlight its significant impact on the healthcare industry worldwide.

In recent years, Teleflex has achieved notable success with a 6.5% constant currency revenue growth in 2023, driven by the expansion of its geographic presence and the launch of innovative new products. The company has strategically acquired Palette Life Sciences AB, enhancing its portfolio and operational efficiencies.

Teleflex remains committed to its mission of providing solutions that improve outcomes and enhance safety for patients and healthcare providers. By leveraging purpose-driven innovation, Teleflex continues to address unmet clinical needs and advance healthcare technologies.

For more information about Teleflex and its comprehensive product offerings, please visit teleflex.com.

Rhea-AI Summary
Teleflex Incorporated (NYSE:TFX) has announced that it will host a conference call to discuss its first quarter financial results and provide an operational update on May 2, 2024. Participants can pre-register for the call and access it through a live audio webcast on the company's website. An audio replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
-
Rhea-AI Summary
Teleflex Incorporated (NYSE:TFX) announces the full market release of the Advanced Tissue Control (ATC) feature on its UroLift™ 2 System for treating benign prostatic hyperplasia (BPH), offering personalized treatment options and enhanced physician control. The FDA-cleared UroLift™ 2 ATC system provides improved tissue manipulation, targeting accuracy, and efficiency, revolutionizing BPH care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary
Teleflex Incorporated commits to achieving net-zero greenhouse gas emissions by 2050, validated by the Science Based Targets initiative. The company aims to reduce absolute emissions by significant percentages by 2032 and 2050, aligning with climate science goals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
none
News
Rhea-AI Summary
Teleflex Incorporated (TFX) declares a quarterly cash dividend of $0.34 per share of common stock, payable on March 15, 2024, to shareholders of record as of March 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
dividends
-
Rhea-AI Summary
Teleflex Incorporated (TFX) reported solid financial results for Q4 2023 and full year 2023, with revenue growth and adjusted EPS exceeding prior year figures. The company provided optimistic guidance for 2024, emphasizing growth strategies and capital allocation. Despite a decrease in GAAP EPS, adjusted EPS is expected to grow in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.28%
Tags
-
Rhea-AI Summary
Liam Kelly, Chairman, President, and CEO of Teleflex Incorporated (TFX), will speak at the 45th Annual Raymond James Institutional Investors Conference. The live webcast will be available on the Teleflex website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
Rhea-AI Summary
Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its fourth quarter financial results and provide an operational update on February 22, 2024. Participants can pre-register and access the call through the company's website or by telephone. An audio replay will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) announced the availability of Titan SGS™ Standard Staple Line Reinforcement with GORE® SEAMGUARD® Bioabsorbable Staple Line Reinforcement, a new option for bariatric surgeons. The product is designed to support staple line strength and reduce leaks or bleeds, expanding device selection for surgeons. The FDA clearance for this product means that surgeons who prefer staple line reinforcement now have that option with the Titan SGS™ Stapler.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary
Teleflex Incorporated (NYSE: TFX) CEO Liam Kelly to Speak at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences
Rhea-AI Summary
Teleflex Incorporated (TFX) has been awarded the Peripheral Access purchasing agreement with Premier, Inc., effective December 1st, 2023. This agreement allows Premier members to take advantage of special pricing and terms for Teleflex’s Peripheral Access products, including Peripherally Inserted Central Catheters (PICCs), PICC navigation equipment, and Midlines. The company is committed to delivering vascular access products designed to benefit clinicians and patients, while protecting against vascular access-related complications. Through its Arrow™ Peripheral Access products, Teleflex has recently refreshed the portfolio to optimize patient outcomes, reduce catheter colonization of major central line-associated infections (CLABSI) causing pathogens, and streamline insertion procedures. The new agreement with Premier is a significant opportunity for Teleflex to continue supporting healthcare providers in their efforts to reduce vascular-related complications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
none

FAQ

What is the current stock price of Teleflex (TFX)?

The current stock price of Teleflex (TFX) is $175.64 as of February 21, 2025.

What is the market cap of Teleflex (TFX)?

The market cap of Teleflex (TFX) is approximately 8.1B.

What does Teleflex Incorporated do?

Teleflex Incorporated is a global provider of specialty medical devices for critical care and surgical procedures, serving healthcare providers in over 150 countries.

Where is Teleflex Incorporated headquartered?

Teleflex Incorporated is headquartered in Wayne, Pennsylvania, USA.

How many people does Teleflex employ?

Teleflex employs approximately 12,000 people worldwide.

What are the main segments of Teleflex's business?

Teleflex operates in seven main segments: vascular access, interventional, anesthesia, surgical, interventional urology, original-equipment manufacturing, and other.

What percentage of Teleflex’s revenue comes from the United States?

About 60% of Teleflex’s revenue comes from the United States.

What recent acquisitions has Teleflex made?

Teleflex recently acquired Palette Life Sciences AB to bolster its portfolio and operational efficiencies.

What is the UroLift™ System?

The UroLift™ System is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that helps preserve patient quality of life.

What was Teleflex's revenue growth in 2023?

Teleflex achieved a 6.5% constant currency revenue growth in 2023.

How can one access Teleflex's investor conference calls?

Teleflex's investor conference calls can be accessed via a live audio webcast on their website, teleflex.com.

What is the mission of Teleflex Incorporated?

Teleflex's mission is to provide solutions that improve outcomes and enhance safety for patients and healthcare providers.
Teleflex Inc

NYSE:TFX

TFX Rankings

TFX Stock Data

8.13B
46.25M
0.28%
99.43%
2.27%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
WAYNE